These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32779201)

  • 1. Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.
    Ji P; Chen J; Golding A; Nikolov NP; Saluja B; Ren YR; Sahajwalla CG
    J Clin Pharmacol; 2020 Oct; 60(10):1275-1293. PubMed ID: 32779201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
    Liu X; Cao W; Li T
    Front Immunol; 2020; 11():1660. PubMed ID: 32760407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation in COVID-19.
    Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
    Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
    Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
    Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
    Front Immunol; 2020; 11():2159. PubMed ID: 32983179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
    Feldmann M; Maini RN; Woody JN; Holgate ST; Winter G; Rowland M; Richards D; Hussell T
    Lancet; 2020 May; 395(10234):1407-1409. PubMed ID: 32278362
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
    Sarzi-Puttini P; Giorgi V; Sirotti S; Marotto D; Ardizzone S; Rizzardini G; Antinori S; Galli M
    Clin Exp Rheumatol; 2020; 38(2):337-342. PubMed ID: 32202240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curing COVID-19.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2020 Oct; 20(10):1101. PubMed ID: 32919520
    [No Abstract]   [Full Text] [Related]  

  • 12. Repurposing Existing Drugs for the Treatment of COVID-19.
    Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A
    Ann Am Thorac Soc; 2020 Oct; 17(10):1186-1194. PubMed ID: 32692580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromelain: A Review on its Potential as a Therapy for the Management of Covid-19.
    Owoyele BV; Bakare AO; Ologe MO
    Niger J Physiol Sci; 2020 Jun; 35(1):10-19. PubMed ID: 33084621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2: a time for clear and immediate action.
    Poland GA
    Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.
    Canham MA; Campbell JDM; Mountford JC
    J Transl Med; 2020 Sep; 18(1):359. PubMed ID: 32958009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulators in COVID-19: Two Sides to Every Coin.
    Snow TAC; Singer M; Arulkumaran N
    Am J Respir Crit Care Med; 2020 Nov; 202(10):1460-1462. PubMed ID: 32926809
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaco-Immunomodulatory Therapy in COVID-19.
    Rizk JG; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Forthal DN
    Drugs; 2020 Sep; 80(13):1267-1292. PubMed ID: 32696108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology.
    Venkatakrishnan K; Yalkinoglu O; Dong JQ; Benincosa LJ
    Clin Pharmacol Ther; 2020 Oct; 108(4):699-702. PubMed ID: 32356569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
    Cleary SJ; Pitchford SC; Amison RT; Carrington R; Robaina Cabrera CL; Magnen M; Looney MR; Gray E; Page CP
    Br J Pharmacol; 2020 Nov; 177(21):4851-4865. PubMed ID: 32462701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.